Immediate Impact
1 from Science/Nature 29 standout
Citing Papers
AXL signaling in cancer: from molecular insights to targeted therapies
2025 Standout
Clinical advances of mRNA vaccines for cancer immunotherapy
2025 Standout
Works of Christopher Massey being referenced
Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
2022
P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Christopher Massey | 58 | 94 | 29 | 64 | 9 | 167 | |
| Susan Houghton | 96 | 72 | 40 | 57 | 7 | 295 | |
| Danielle Cohen | 42 | 47 | 40 | 40 | 13 | 175 | |
| Mariela Blum‐Murphy | 41 | 133 | 28 | 95 | 9 | 227 | |
| Cosette D. Champion | 25 | 113 | 27 | 104 | 10 | 253 | |
| Beverly Schmocker | 60 | 79 | 33 | 132 | 6 | 252 | |
| Heike Zabeck | 39 | 82 | 62 | 146 | 11 | 269 | |
| Servando Fernández-Díez | 20 | 63 | 45 | 49 | 10 | 178 | |
| J.D. Grange | 56 | 58 | 35 | 60 | 13 | 252 | |
| Patrick Brunhoeber | 39 | 108 | 60 | 29 | 9 | 192 | |
| Luiz Fernando Teixeira | 72 | 46 | 60 | 37 | 15 | 277 |
All Works
Loading papers...